Semaglutide Effects on Sleep Apnea in Patients With Type 2 Diabetes/Obesity and Comorbid Obstructive Sleep Apnea

Conditions

• Sleep Apnea Syndrome (OSAS)

Eligibility Criteria

Sex

ALL

Age

18 Years - 65 Years

Healthy Volunteers

Not accepted

Interventions

• Semaglutide Subcutaneous Injection — DRUG
  This study is a observational study and the treatments are based on the clinical practice. In the study, patients with treatments were recorded. According to the instructions of drugs, 1ml of the injection contains 1.34mg of semaglutide. Each pre-filled injection pen contains 2mg of semaglutide and is placed in 1.5ml of solution. This product should be injected once a week.

Study Details

Semaglutide (a GLP-1RA) is approved for type 2 diabetes mellitus T2DM and obesity, but its effect on obstructive sleep apnea OSA remains unclear. To evaluate changes in Apnea-Hypopnea Index (AHI) after 1-week and 4-week semaglutide treatment in T2DM/obesity patients with OSA, we conducted a single-center real-world study (RWS) of 15 patients. Outcomes assessed included AHI, weight, BMI, blood pressure, blood glucose (fasting blood glucose, glycated albumin), liver function, blood lipids, waist circumference, and other metabolic parameters, to provide real-world evidence for semaglutide in OSA management.

Key Dates

Start date

Jan 1, 2025

Status verified

Apr 2026

Primary completion

Dec 31, 2025

Completion

Jan 31, 2026

Study Design

Enrollment

15 participants (actual)

Arms

• Arm: Semaglutide Treatment Group
  single-arm cohort of 15 patients with T2DM/obesity and OSA receiving semaglutide (0.25-2.4mg/week) for 4 weeks

Primary Outcome Measure

Changes in Apnea-Hypopea Index (AHI) [ Time Frame: Baseline and 1 week ]